Biotech Stock Investor News; Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

New York, New York - July 30, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a.

Select Stock Trading Data
Recent Stock Price:	$0.34
Shares Outstanding:	48.7 million
Float	13.9 million
Recent Market Cap:	$16.8 million
52 Week Range:	$0.12 - $1.45
Exchange:	OTCBB
Ticker:	SBFM
URL:	http://www.sunshinebiopharma.com
Data sourced from Yahoo! Finance; otcbb.com; Company filings

Sunshine Bipharma, Inc. (SBFM) is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. SBFM reports that the preclinical studies for the Company's lead compound, Adva-27a, a multi-purpose anti-tumor compound, were successfully completed in late 2011. SBFM is now continuing the clinical development of Adva-27a by conducting the next sequence of steps comprised of GMP manufacturing, IND-enabling studies, regulatory filing and Phase I clinical trials. SBFM plans to conduct Phase I clinical trials for Adva-27a at the Jewish General Hospital, Montreal, Canada, one of McGill University's Hospital Centers.
The planned indication will be multidrug resistant breast cancer as SBFM reports that Adva-27a has shown remarkably strong cytotoxic activity against this type of cancer. In addition, on June 26, 2012, SBFM announced the completion of another cytotoxicity study in which Adva-27a was found to be significantly more effective at killing multidrug resistant small-cell lung cancer (SCLC) cells than etoposide, a drug commonly used currently for treating SCLC.
SBFM has licensed its technology on an exclusive basis from Advanomics Corporation and is planning to initiate its own research and development program as soon as practicable
An article in nature biotechnology summarizes the challenge multidrug resistance creates for developing effective treatments:
"Multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, and lower gastrointestinal tract cancers. Tumors usually consist of mixed populations of malignant cells, some of which are drug-sensitive while others are drug-resistant. Chemotherapy kills drug-sensitive cells, but leaves behind a higher proportion of drug-resistant cells. As the tumor begins to grow again, chemotherapy may fail because the remaining tumor cells are now resistant."
As explained in an article published by the National Institutes of Health (NIH), this cellular response to toxins in the environment is critical for our survival and has evolved over time:
"Toxins in the environment are a major threat to many living organisms. Once internalized, toxic compounds must be removed for the organisms to survive. Therefore, humans have developed, inherited and perfected ways to reduce the effect of xenobiotics. At the cellular level, the cell membrane acts as a physical barrier to prevent compounds from entering the cell. However, because some compounds can diffuse through the cell membrane, alternative protective methods have evolved. One of the most important defense mechanisms is to pump xenobiotics out of the cells. Thus, drug transporters are commonly found in the cell membranes of many organisms, from bacteria to mammals, and are responsible for cell protection. However, the existence of these drug transporters often hinders the use of compounds used to treat diseases because they are substrates of these efflux pumps either by affecting the pharmacokinetics of drugs in the body or by limiting accumulation in target cells such as cancer cells."
SBFM reports that Adva-27a can overcome two of these xenobiotic pumps - multidrug resistant transporter proteins MDR1 and MRP1, which facilitate multidrug resistance, and as the NIH article notes, MDR1 in particular has become the most studied gene in the field of multidrug resistance.
In terms of gauging the potential market opportunity for Adva-27a for use in the treatment of breast cancer, Roche's Herceptin® reached $5.3 billion a year in sales in 2011. Herceptin® is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+), which the National Cancer Institute estimates represents only 15% - 20% of breast cancer patients. The American Cancer Society estimates that in the U.S. alone, there will be 229,060 new cases of breast cancer diagnosed in 2012, with 39,920 deaths from breast cancer during the year. Given that Herceptin® revenue grew by 9% in 2011 and has risen over 30% since 2006, it seems clear there is a very significant market opportunity for a drug that is effective for the non-HER2+ breast cancer population, which represents a significant majority of breast cancer patients.
As reference for the potential market opportunity for Adva-27a for treatment of small-cell lung cancer, the American Cancer Society estimates there will be 226,160 new cases of lung and bronchus cancer in the U.S. in 2012, with an estimated 160,340 deaths. The National Cancer Institute (NCI) estimates that small-cell lung cancer (SCLC) accounts for approximately 15% of bronchogenic carcinomas. While etoposide, now available as a generic, is used in combination with other medications to treat SCLC, the NCI addresses the challenge and urgency of developing a more effective treatment for SCLC, noting that:
"Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory despite improvements in diagnosis and therapy made during the past 25 years. Without treatment, SCLC has the most aggressive clinical course of any type of pulmonary tumor, with median survival from diagnosis of only 2 to 4 months."
"For most patients with small cell lung cancer, current treatments do not cure the cancer. If lung cancer is found, patients should think about taking part in one of the many clinical trials being done to improve treatment. Clinical trials are taking place in most parts of the country for patients with all stages of small cell lung cancer."
In a recent interview, SBFM CFO Camile Sebaaly noted that the Company expects the first clinical trial of Adva-27a will be done on breast cancer volunteers at Jewish General Hospital. As the Company continues to do the work and raise the capital necessary to bring its drug to market, Mr. Sebaaly stated that the Company expects that if FDA approval is obtained, SBFM may have a similar sales profile to other important cancer drugs that have reached $1 billion in sales within 2 years of FDA approval.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $510 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Visit the SBFM profile http://www.investorideas.com/CO/SBFM/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th/
Patrick Murphy was compensated five hundred dollars for the CFA commentary article
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Healthcare and Medical Stock; Comprehensive Care (OTC:CHCR) Expects $18 Million in Revenue and Profitability for Second Quarter

TAMPA, Fla. - July 27, 2012 (Investorideas.com newswire) - Healthcare stock news: Comprehensive Care Corporation (OTCBB: CHCR) reported in late June that it expects to report a profit for the second quarter of 2012, with revenues for the quarter of approximately $18 million. Revenues for the same quarter in 2011 were $18.6 million. However, during that quarter, the Company posted a loss of $4 million.

Commenting on the expected results for the quarter, Robert J. Landis, CompCare's Chief Financial Officer, stated: "The Company is particularly excited about our second quarter expected results since, if realized, it will be the first time in many years that the Company has been able to post a profit for two consecutive quarters. The improvement in results from the second quarter of 2011 to the second quarter of 2012, we believe, is primarily attributable to our Pharmacy Management Program which is now achieving traction and our cost reduction efforts to streamline our internal systems. Part of the shift in the pharmacy program occurred from our establishing Company-owned clinics in areas where we experience high patient utilization and cost. The clinics have the effect of reducing those costs and providing us with a greater opportunity to directly service the needs of the patients. Based on our best current available information, for example, the Company expects to realize a profit in its at-risk pharmacy operations in April, and this trend continues in May where preliminary numbers indicate an increase profit in the Company's at-risk pharmacy operations. While there can be no assurances that this trend will continue or that there might not be subsequent positive or negative adjustments to the April and May results, the upward trend is what we were looking for since we believe that it indicates the viability of the overall program. Other aspects of the Pharmacy Management Program are in the process of being implemented and will occur shortly."
Mr. Landis continued, "Another aspect of the Pharmacy Management Program that contributed to a successful second quarter was the signing of a Third Amendment (the "Amendment") to a material agreement with one of our existing, at-risk pharmacy clients. As a result of the Amendment, the Company received a $2.2 million, retroactive, cash adjustment to pharmacy prescriptions, which were originally charged to the Company. Additionally, the Amendment shifts the financial responsibility for a significant number of prescriptions from the Company to the client for the remainder of 2012. We expect this financial responsibility shift to further reduce the Company's pharmacy expenses throughout the year, and although there can be no guarantees that these expectations will be achieved, we expect the shift to further enhance the Company's profitability in its pharmacy operations for the remainder of 2012."
"Additionally, we were able to implement administrative, cost-saving measures that also contributed to a profitable second quarter," Mr. Landis said.
Revenue and other financial estimates contained in this press release have not been audited or reviewed by the Company's independent auditors, and accordingly they express no opinion or other form of assurance as to this information. The Company provides no assurance that these preliminary results, future expectations or assumptions will be met for the second quarter or fiscal year 2012. The Amendment addresses a number of other aspects of the Company's business with its client. A complete copy of the Amendment has been filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
About CompCare
Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States . Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release, including but not limited to our expected profitability in the second quarter of 2012, the continued implementation of our Pharmacy Management Program, the impact of the financial responsibility shift with one of our existing, at-risk pharmacy clients, our ability to increase margins and to obtain sustainable profitability, our ability to reduce overhead and implement further cost savings, our ability to further improve the Company's performance, the outcome of our business strategy, our ability to expand our pharmacy management program with higher profit margins, and our ability to reduce pharmacy expenses throughout the year are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new and existing business, our ability to expand and manage our provider network, the profitability, if any, of our recently acquired or previously existing capitated contracts, the costs incurred in seeking new contracts, the loss or termination of any existing contract, increases or variations in cost of care, seasonality, the Company's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
949.707.5365

Published at Investorideas.com Newswire

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk. Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors

SAN DIEGO - July 27, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Thomas V. Wornham and Philip A. Ward to its board of directors. "We are honored to have Tom and Phil join our board. Their wealth of business experience will be instrumental in guiding the future growth and achievement of our organization," stated Aethlon Chairman & CEO Jim Joyce.

Mr. Wornham recently retired as Executive Vice President & Regional Manager at Wells Fargo Bank in San Diego, representing the culmination of an exemplary career that spanned three decades. At Wells Fargo, Tom's team provided financial solutions to diverse industry organizations whose annual revenues ranged between $10 million to $1 billion dollars. Included among these organizations were public and private life science, biotechnology and medical device companies located throughout San Diego, Imperial, and Southern Riverside Counties. Mr. Wornham is also an active civic leader. He is currently Vice Chairman of the San Diego Water Authority and the past Chairman of the San Diego Regional Chamber of Commerce, The Century Club of San Diego, and the San Diego Regional Economic Development Corporation. Mr. Wornham graduated from University of California Berkeley, with a BA Political Science.
"This is a tremendous opportunity for me to work with Jim and his team," stated Mr. Wornham. "I am excited to be part of a group committed to developing technology that I hope will improve the quality of peoples lives."
Mr. Ward is the former Chairman and CEO, Bignell-Ward-Bignell Corporation; former President and CEO, Hawk Financial Services Corporation, A premium finance company; Former Executive Director and COO of Investments, Golden Eagle Insurance Corporation, a property and casualty California insurance company; and former Executive Vice President and COO Finance at Big Bear Supermarkets, where he was also in charge of acquisitions, as well as leasing and sales of all operating units and real properties.
"I believe in the vision of Aethlon Medical and I look forward to contributing my business acumen to the benefit of shareholders," stated Mr. Ward.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Healthcare Stock To Watch: Comprehensive Care (OTCBB: CHCR)

New York, NY - July 27, 2012 (Investorideas.com newswire) - Healthcare stock spotlight at Investorideas.com: InvestorIdeas.com, a global investor research portal for independent investors, releases a company snapshot for microcap Healthcare Stock, Comprehensive Care Corporation (OTCBB: CHCR). The small OTC Company recently made headlines reporting that Florida Trend magazine has ranked CompCare one of the top three big movers among publicly-traded companies in Florida.
Yesterday’s trading saw the Company trade up over 6%. The 52 week range is $ 0.10 - 0.30. The stock has just fewer than 60 Million shares outstanding and a float of just over 15 Million shares.
What the analysts say:
Research from SmallCaps.Us and Breakdown and Highlights on CHCR
"Comprehensive Care Corporation (CompCare) provides managed care services in the behavioral health, substance abuse, and psychotropic pharmacy management fields to Medicare, Medicaid, Children's Health Insurance Programs and other commercial health plans.

Regional health plans, which typically don't have their own behavioral health network, will often contract with a Managed Behavioral Healthcare Organization (MBHO) like CompCare, to obtain access to behavioral healthcare professionals, claims processing, case management, better-integrated behavioral healthcare, and psychotropic pharmacy management services.
Although Comprehensive Care was established in 1969, its attractiveness today is an in-progress turnaround that started in 2009 when the current management team took a controlling position in the Company.
The first thing the new management did was get rid of money-loosing contracts. As a result, revenues dropped from over $35 million in 2008 to approximately $14 million in 2009. Next, management members invested approximately $20 to restructure the Company.
They revamped the IT infrastructure and transitioned the Company from processing claims manually, to processing them electronically at a much lower cost. They streamlined operations and expanded their service provider network from 10,000 healthcare participants in 25 states to 35,000 healthcare participants in 46 states, Puerto Rico and theDistrict of Columbia.
All these efforts beared fruit, as revenues quintupled to $71 million in fiscal year 2011, up from $14 million in 2009.
In 2012, the Company is focusing on digesting all its revenue growth and returning to profitability. So far it has been very successful in doing so. In the first quarter of 2012, earnings almost doubled to $80,000, compared with $41,000 in the same period last year. And for the second quarter, which ended a few days ago, the management expects to be profitable whereas it posted a loss of almost $4 million in the second quarter of 2011.
Moreover, because the behavioral healthcare services industry is very price competitive, the Company sought and found a way to get into the higher margin commercial pharmaceuticals delivery market. CompCare contracts with PBMs to obtain the lowest possible prices for both branded and generic drugs, which results in significant cost savings for CompCare's clients." Source and Opinion of: * http://www.smallcaps.us
About CompCare (OTCBB: CHCR) Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Profile page at Investorideas.com
http://www.investorideas.com/CO/CHCR/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk . The opinion of smallcaps.us is not the opinion or research of Investorideas.com Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Medical Technology Stock News Alert; PositiveID Corporation (OTCBB: PSID) Adds Chief Technology Advisor and Biodefense Expert as it Prepares for $3.1 Billion BioWatch Procurement

DELRAY BEACH, FL - July 25, 2012 - (Investorideas.com Newswire) PositiveID Corporation ("PositiveID" or “Company”) (OTCBB: PSID), an emerging growth company and developer of sophisticated airborne bio-threat detection systems for America’s homeland defense, today announced it has added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems (“MFS”) subsidiary. The Company will utilize Dr. Smith’s expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security (“DHS”) for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.

Dr. Smith has served as a Senior Advisor for International Biodefense for DHS’ Office of Health Affairs and was detailed to the U.S. State Department Office of International Health and Biodefense. Prior to this he served as the Acting Director of the National Biosurveillance Integration Center, where he set the vision and strategy of a U.S. government-wide effort to acquire, aggregate, integrate, analyze, interpret and disseminate all-source biosurveillance information from governmental and private sectors for epidemiological analyses and health protection.
Recently Dr. Smith was as a Senior Scientist for the Tahoe Research Initiative LLC, where he worked on global biosurveillance issues to build capacity and capability of public and veterinary health systems. Moreover, he was the Department of Homeland Security's first Chief Veterinarian and served as the Chief Scientist for the Office of Health Affairs. Prior to working with DHS, Dr. Smith worked at Lawrence Livermore National Laboratory LLNL, where he served as the Deputy Division Leader for Operations in the Counter-terrorism and Incident Response Division of the Non-proliferation, Arms Control and International Security Directorate. In this capacity Dr. Smith was responsible for maintenance and readiness of the laboratory’s nuclear response deployment and assessment teams. He earned his Ph.D. in molecular epidemiology from Louisiana State University (1999) where he curated the worldwide Bacillus anthracis collection.
William J. Caragol, Chairman and CEO of PositiveID, said, “We believe that Kimothy’s deep knowledge and experience in bioterrorism and biodefense strengthens our team as we move toward this important program.”
The Company’s M-BAND system was recently featured in a Bloomberg Businessweek article on the BioWatch procurement by DHS and can be read at:
http://www.businessweek.com/ articles/ 2012-06-21/ the-sky-high-price-of -sniffing-out-anthrax.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Investor News Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

New York, New York - July 24, 2012 (Investorideas.com newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues follow-up commentary from Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) following recent news from the Company. Sunshine Biopharma reported it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Sunshine Biopharma's lead compound, Adva-27a, is a highly specific Topoisomerase II (Top2) Inhibitor and has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Q: Investorideas.com staff
Camille, your Company announced on July 20 th that it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. To the novice investor, can you explain what the significance of this is towards the development of Adva-27a as an actual drug?
A: Mr. Camille Sebaaly, CFO
At the end of the month, Sunshine Biopharma will take delivery from Beta Pharma Canada two items:

• Adva-27a Compound
• Scale-up Manufacturing Protocol

The Adva-27a Compound part of the delivery is the actual Adva-27a drug which Beta Pharma Canada had synthesized and put through rigorous structure validation and chemical characterization processes including HPLC, Mass Spec and NMR (H, F, COSY, HMQC) analyses. Sunshine Biopharma will perform specific biological analyses on the material for confirmation of biological activity. These are standard procedures in initial drug manufacturing processes.
The Scale-up Manufacturing Protocol, which is the second part of the delivery from Beta Pharma Canada, will be vetted by Sunshine Biopharma then transferred to the large-scale (over 1 kilogram range) manufacturer for large-scale process development and manufacturing under GMP conditions. The material produced under GMP conditions will be used by Sunshine Biopharma to conduct IND-Enabling Studies and Phase I Clinical Trials in humans.
Read Investorideas.com First Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Beta Pharma Canada
Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Homeland Defense and Security Q&A Interview with PositiveID (OTCBB: PSID): How the M-BAND System Biothreat Detection is in the Running for BioWatch

New York, NY - July 23, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID) discussing its M-BAND System for biothreat detection.

Q: Investorideas.com
Can you briefly explain to new investors how the M-BAND System works and how it can be deployed in the BioWatch Generation 3 program?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our Microfluidics-based Bioagent Networked Detector, called M-BAND, was developed under contract for the Department of Homeland Security (DHS), and is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days between service cycles, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for instruments in the field in aggregate. M-BAND was designed with a high level of operational flexibility, and can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.
Q: Investorideas.com
We understand the Department of Homeland Security wants to open bidding before October for Generation 3 of the BioWatch program, now estimated at $5.7 Billion. Where is PSID in the process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are currently awaiting the final RFP from the Department of Homeland Security, which is expected to be released later this year. In the meantime, we have made significant progress in our internal testing of M-BAND, which detects five organisms on the Centers for Disease Control Select Agents List, which is a requirement for BioWatch. Our system is fully functional and, we believe, one of the only technologies capable of addressing the requirements of the BioWatch procurement. We are preparing for potential additional testing of our system as well.
Q: Investorideas.com
The other company bidding for the BioWatch program is Northrop Grumman (NYSE:NOC); is this competitive against your technology or more synergistic?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe the M-BAND instrument offers a number of advantages over similar products, including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation. M-BAND has been designed and field tested (both indoors and outdoors) to operate continuously for 30 days unattended between scheduled services, which we believe to be higher than competing technologies. It also operates using industry gold-standard TaqMan® PCR (polymerase chain reaction) chemistry.
Q: Investorideas.com
Your Company was recently featured in a Bloomberg Businessweek.com article discussing BioWatch; did that lend a new level of credibility for your company being a small OTC listed stock?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe articles like the one published in Bloomberg Businessweek shed light on the need for BioWatch Generation 3, and also highlight and validate our technology and our company. Many people may not have been previously aware of PositiveID or M-BAND, so it was very significant for our company and technology to be featured alongside the likes of Northrop Grumman. We have already received additional inquiries and interest from large corporations around the world including for possible partnership opportunities, as well as increased investor interest.
Q: Investorideas.com
Are you targeting any other markets forthe M-BAND System globally?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, terrorism is not limited to the United States, so M-BAND could be deployed in any location around the globe. In fact, the system has been field tested in London.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894